CIPRIANI, Sabrina
 Distribuzione geografica
Continente #
NA - Nord America 2.890
AS - Asia 1.985
EU - Europa 1.698
SA - Sud America 298
AF - Africa 46
OC - Oceania 4
Totale 6.921
Nazione #
US - Stati Uniti d'America 2.817
SG - Singapore 959
IE - Irlanda 320
IT - Italia 297
CN - Cina 292
RU - Federazione Russa 247
HK - Hong Kong 241
BR - Brasile 233
VN - Vietnam 216
UA - Ucraina 157
FR - Francia 131
SE - Svezia 127
DE - Germania 94
FI - Finlandia 93
GB - Regno Unito 64
IN - India 54
TR - Turchia 50
CA - Canada 36
EE - Estonia 36
KR - Corea 28
MX - Messico 25
PL - Polonia 25
AR - Argentina 24
BD - Bangladesh 23
JP - Giappone 17
IQ - Iraq 16
CH - Svizzera 15
AT - Austria 14
ES - Italia 14
NL - Olanda 14
PK - Pakistan 14
RO - Romania 14
UZ - Uzbekistan 13
ZA - Sudafrica 13
EC - Ecuador 11
PH - Filippine 11
BE - Belgio 10
CO - Colombia 10
CZ - Repubblica Ceca 9
ID - Indonesia 8
LB - Libano 7
SA - Arabia Saudita 7
EG - Egitto 6
KE - Kenya 6
VE - Venezuela 6
CL - Cile 5
GR - Grecia 4
LT - Lituania 4
CR - Costa Rica 3
DZ - Algeria 3
ET - Etiopia 3
HN - Honduras 3
KG - Kirghizistan 3
MA - Marocco 3
MY - Malesia 3
NP - Nepal 3
PA - Panama 3
PE - Perù 3
PY - Paraguay 3
TN - Tunisia 3
TW - Taiwan 3
AU - Australia 2
BN - Brunei Darussalam 2
HU - Ungheria 2
IL - Israele 2
JO - Giordania 2
NG - Nigeria 2
NO - Norvegia 2
PS - Palestinian Territory 2
SN - Senegal 2
TH - Thailandia 2
UY - Uruguay 2
AL - Albania 1
AO - Angola 1
AZ - Azerbaigian 1
BF - Burkina Faso 1
CI - Costa d'Avorio 1
CV - Capo Verde 1
DO - Repubblica Dominicana 1
IR - Iran 1
JM - Giamaica 1
KH - Cambogia 1
KZ - Kazakistan 1
LU - Lussemburgo 1
LY - Libia 1
MD - Moldavia 1
MN - Mongolia 1
NR - Nauru 1
OM - Oman 1
PT - Portogallo 1
PW - Palau 1
QA - Qatar 1
RS - Serbia 1
SR - Suriname 1
SV - El Salvador 1
Totale 6.921
Città #
Singapore 720
Chandler 396
San Jose 332
Dublin 319
Hong Kong 240
San Mateo 193
Ashburn 173
Dong Ket 134
Santa Clara 110
Perugia 109
Boardman 101
Moscow 93
Beijing 92
Ann Arbor 90
Altamura 88
Medford 78
Princeton 78
Jacksonville 69
Lawrence 69
Lauterbourg 67
Wilmington 64
Andover 63
Los Angeles 51
Columbus 33
New York 33
Izmir 32
São Paulo 31
The Dalles 30
Des Moines 27
Saint Petersburg 27
Seoul 27
Ho Chi Minh City 25
Munich 23
Dearborn 22
Helsinki 22
Orem 22
Warsaw 18
Houston 16
Tokyo 16
Hanoi 15
Dallas 14
Timisoara 14
Chennai 13
London 13
Stockholm 13
Frankfurt am Main 12
San Paolo di Civitate 12
Norwalk 11
Redmond 11
Rio de Janeiro 11
Rome 11
Brussels 10
Chicago 10
Falls Church 10
Johannesburg 10
Manchester 10
Nuremberg 10
Denver 9
Mexico City 9
Montreal 9
Toronto 9
Vienna 9
Woodbridge 9
Den Haag 8
Turku 8
Ankara 7
Baghdad 7
Boston 7
Council Bluffs 7
Olomouc 7
Phoenix 7
Redwood City 7
Tashkent 7
Brooklyn 6
Guayaquil 6
New Delhi 6
San Francisco 6
Buffalo 5
Nairobi 5
Ottawa 5
Paris 5
Ribeirão Preto 5
Seattle 5
Shanghai 5
Campinas 4
Da Nang 4
Dhaka 4
Nanjing 4
Ninh Bình 4
Piscataway 4
Quito 4
Addis Ababa 3
Amsterdam 3
Atlanta 3
Bexley 3
Bishkek 3
Bắc Ninh 3
Cairo 3
Carney 3
Chandigarh 3
Totale 4.583
Nome #
The bile acid receptor GPBAR1 (TGR5) is expressed in human gastric cancers and promotes epithelial-mesenchymal transition in gastric cancer cell lines 147
Anti-HIV Protease Inhibitors Interact With NSAIDs and Exacerbate Small Intestine Enteropathy Induced by NSAIDs 147
Activation of the bile acid receptor GPBAR1 protects against gastrointestinal injury caused by non-steroidal anti-inflammatory drugs and aspirin in mice. 146
The bile acid receptor GPBAR1 regulates the M1/M2 phenotype of intestinal macrophages and activation of gpbar1 rescues mice from murine colitis 142
A Comprehensive Analysis of Small Heterodimer Partner (SHP) Target Genes in Hepatic Stellate Cells and the Discovery of a New Class of SHP Agonists That Reduces Liver Fibrosis 141
BAR502, a Dual FXR and GPBAR1 Agonist, Reverses Steatosis and Fibrosis in Rodent Model of NASH By Modulating Authophagic Genes 138
Bile acid-activated receptors in the treatment of dyslipidemia and related disorders. 135
Microencapsulated G3C hybridoma cell graft delays the onset of spontaneous diabetes in NOD mice by an expansion of Gitr+ Treg cells 132
Activation of the farnesoid-X receptor protects against gastrointestinal injury caused by non-steroidal anti-inflammatory drugs in mice. 130
Activation of FXR Improves Myocardial Fatty Acid Metabolism in a Rodent Model of Liver Steatosis 128
BAR 501, a Novel GPBAR1 Ligand, Reverses Intestinal and Liver Inflammatory Models Demonstrating That GPBAR1 Is an Essential Modulator of Innate Immunity in Entero-Hepatic Tissues 123
Leflunomide protects against dyslipidemia development induced by ritonavir in mice 122
Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice. 120
Dissociation of intestinal and hepatic activities of FXR and LXRα supports metabolic effects of terminal ileum interposition in rodents. 110
BAR501, A SELECTIVE GPBAR1 AGONIST, PROMOTES ADIPOSE TISSUE BROWNING AND AUTOPHAGY AND IMPROVES LIPID METABOLISM AND STEATO-HEPATITIS IN MICE FEED A HIGH FAT DIET 109
A Platelet's Guide to Synovitis 109
Glucocorticoid receptor mediates the gluconeogenic activity of the farnesoid X receptor in the fasting condition 106
BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis 104
Genetic and Pharmacological Dissection of the Role of Spleen Tyrosine Kinase (Syk) in Intestinal Inflammation and Immune Dysfunction in Inflammatory Bowel Diseases 104
Bile acid activated receptors are targets for regulation of integrity of gastrointestinal mucosa 103
BAR130, A HYODEOXYCHOLIC ACID DERIVATIVE AS THE FIRST EXAMPLE OF DUAL LXR alpha/GPBAR1 AGONIST 103
Counter-regulatory role of bile acid activated receptors in immunity andinflammation. 101
Development of non-antibiotic macrolide that corrects inflammation-driven immune dysfunction in models of inflammatorybowel diseases and arthritis 99
Maraviroc Intensification Modulates Atherosclerotic Progression in HIV-Suppressed Patients at High Cardiovascular Risk. A Randomized, Crossover Pilot Study 98
Probiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activation. 96
Genetic Ablation and Pharmacological Blockade of CCR5 by the anti-HIV Small Molecule Inhibitor Maraviroc Inhibits Leukocyte Trafficking and Protects Against Mucosal Inflammation in Murine Models Colitis 96
A Novel Source of Intestinal Damage: The HIV Protease Inhibitor Ritonavir Worsens Damage Caused by COX Inhibitors 95
Discovery that theonellasterol a marine sponge sterol is a highly selective FXR antagonist that protects against liver injury in cholestasis. 95
DISCOVERY OF BAR704, A POTENT AND SELECTIVE FXR AGONIST, THAT PROTECTS AGAINST LIVER FIBROSIS 94
The HIV Matrix Protein p17 subverts Nuclear Receptors Expression and induces a STAT1-Dependent Proinflammatory Phenotype in Monocytes 93
The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis. 92
Farnesoid X receptor suppresses constitutive androstane receptoractivity at the multidrug resistance protein-4 promoter. 90
Metabolic variability of a multispecies probiotic preparation impacts on the anti-inflammatory activity 90
The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. 90
The bile acid sensor FXR protects against dyslipidemia and aortic plaques development induced by the HIV protease inhibitor ritonavir in mice. 88
Ritonavir-induced lipoatrophy and dyslipidaemia is reversed by the anti-inflammatory drug leflunomide in a PPAR-γ-dependent manner. 88
Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. 88
FXR mediates a chromatin looping in the GR promoter thus promoting the resolution of colitis in rodents. 87
Gpbar1 agonism promotes a Pgc-1α-dependent browning of white adipose tissue and energy expenditure and reverses diet-induced steatohepatitis in mice 87
Nanotraps with biomimetic surface as decoys for chemokines 87
The HIV Matrix Protein p17 promotes the Activation of human hepatic stellate cells through interactions with CXCR2 and Syndecan-2 85
CCR5 Antagonism by Maraviroc Reduces the Potential for Gastric Cancer Cell Dissemination. 84
Targetting farnesoid-X-receptor: from medicinal chemistry to disease treatment. 83
Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GP-BAR1) ligands 83
The nuclear receptor FXR regulates hepatic transport and metabolism of glutamine and glutamate 82
Cystathionine gamma-lyase, a H2S-generating enzyme, is a GPBAR1-regulated gene and contributes to vasodilation caused by secondary bile acids 82
The Leukemic Isocitrate Dehydrogenase (IDH) 1/2 Mutations Impair Myeloid and Erythroid Cell Differentiation of Primary Human Hematopoietic Stem and Progenitor Cells (HSPCs) 81
Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA 81
Impaired Itching Perception in Murine Models of Cholestasis Is Supported by Dysregulation of GPBAR1 Signaling 80
VARIABILITY IN INDUSTRIAL PRODUCTION AFFECTS PROBIOTICS ACTIVITY: IDENTIFICATION OF BATCHES OF PROBIOTIC VSL#3 THAT INCREASES INTESTINAL PERMEABILITY AND WORSENS COLITIS IN RODENTS 78
In vivo administration of ritonavir worsens intestinal damage caused by cyclooxygease inhibitors. 76
Decoding the role of the nuclear receptor SHP in regulating hepatic stellate cells and liver fibrogenesis 76
Hydrogen sulphide induces micro opioid receptor-dependent analgesia in a rodent model of visceral pain. 74
SHP-dependent and -independent induction of peroxisomeproliferator-activated receptor-γ by the bile acid sensor farnesoid X receptorcounter-regulates the pro-inflammatory phenotype of liver myofibroblasts. 73
Modulation of intestinal microbiota by the probiotic VSL#3 resets brain gene expression and ameliorates the age-related deficit in LTP. 73
GPBAR1 (TGR5) LIGATION PROTECTS AGAINST COLITIS DEVELOPMENT BY REGULATING LEUKOCYTE TRAFFINKING AND PROMOTING A IL-10 DEPENDENT SHIFT IN THE M1/M2 PHENOTYPE 72
Instruction of Intestinal Microbiota by VSL#3 Reverses NASH and Accelerated Atherosclerosis Caused by Intestinal Inflammation in ApoE(-/-) Mice 71
H2S Induces Analgesia Is Mediated In Vivo Activation of mu Opioid Receptor and PI3K/AKT Pathway Activation 71
Targeting Bile Acid Receptors: Discovery of a Potent and Selective Farnesoid X Receptor Agonist as a New Lead in the Pharmacological Approach to Liver Diseases 71
Pregnane-X-receptor mediates the anti-inflammatoryactivities of rifaximin on detoxification pathways in intestinal epithelialcells. 70
FXR Activation Reverses Insulin Resistance and Protects Against NASH Development 70
Solomonsterol A, a marine pregnane-X-receptor agonist, attenuates inflammation and immune dysfunction in a mouse model of arthritis. 69
Methotrexate improves endothelial function in early rheumatoid arthritis patients after 3 months of treatment 68
The HIV matrix protein p17 induces hepatic lipid accumulation via modulation of nuclear receptor transcriptoma 68
Role of Maraviroc in a dyslipidemic murine model of atherosclerosis RTV-induced 66
Highly specific blockade of CCR5 inhibits leukocyte trafficking and reduces mucosal inflammation in murine colitis 65
Dietary habits and semen parameters: a systematic narrative review 63
Preterm Birth, Low Gestational Age, Low Birth Weight, Parity, and Other Determinants of Breech Presentation: Results from a Large Retrospective Population-Based Study 63
Essential Role of DNAX Adaptor Protein 12 (DAP12) and Spleen Tyrosine Kinase (Syk) in Inflammation-Driven Immune Dysfunction in Rodent Model of Colitis 62
Reversal of Endothelial Dysfunction by GPBAR1 Agonism in Portal Hypertension Involves a AKT/FOXOA1 Dependent Regulation of H2S Generation and Endothelin-1 62
The bile acid sensor FXR is required for immune-regulatory activities of TLR-9 in intestinal inflammation 58
The Bile Acid Receptor TGR5 Maintains Gastrointestinal Homeostasis and Its Activation Rescues From Gastrointestinal Injury Caused by ASA and NSAIDs 57
VSL#3 Resets Insulin Signaling and Protects against NASH and Atherosclerosis in a Model of Genetic Dyslipidemia and Intestinal Inflammation. 56
Probiotics VSL#3 protect against development of visceral pain in murine model of irritable bowel syndrome. 56
Modification on ursodeoxycholic acid (UDCA) scaffold. discovery of bile acid derivatives as selective agonists of cell-surface G-protein coupled bile acid receptor 1 (GP-BAR1). 54
Reciprocal Regulation of TLRS and Nuclear Receptors: IRF-7 Dependent Regulation of FXR Mediates Counter-Regulatory Effects of TLR-9 in Colitis 52
FXR Activation Corrects Immune-Dysfunction and Attenuates Inflammation in a Rodent Model of Hepatitis 50
Modification of Intestinal Microbiota by VSL#3 Protects Against Development of Pain in the Neonatal Maternal Separation Model. a Whole Genome Array Investigation 48
Hyodeoxycholic acid derivatives as liver X receptor α and G-protein-coupled bile acid receptor agonists 46
Mechanistic role of p38 MAPK in gastric cancer dissemination in a rodent model peritoneal metastasis. 45
EXTRAMEDULLARY INVOLVEMENT IN PATIENT-DERIVED XENOGRAFT MODELS OF ACUTE MYELOID LEUKEMIA (AML) WITH NUCLEOPHOSMIN (NPM-1) MUTATION 16
Totale 7.093
Categoria #
all - tutte 32.761
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.761


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021149 0 0 0 0 0 0 0 0 0 0 0 149
2021/2022676 7 132 2 34 31 7 14 223 8 32 85 101
2022/20231.223 81 243 7 124 115 116 0 62 431 1 32 11
2023/2024394 31 52 25 3 2 2 97 13 10 20 84 55
2024/20251.161 16 88 47 42 166 66 28 69 231 71 196 141
2025/20262.482 152 145 145 270 325 216 464 145 334 213 70 3
Totale 7.093